The global blood plasma derivatives market reached a value of US$ 40.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 59.8 Billion by 2027, exhibiting a CAGR of 6.40% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Blood plasma derivatives are concentrates of specific proteins prepared from plasma that are obtained through fractionation process. Factor VIII, immunoglobulin, albumin, hyperimmune globulin, factor IX and fresh frozen are some of the common blood plasma derivatives. They are rich in proteins, minerals, salts, hormones, vitamins and protease inhibitors, due to which they are widely used to kill viruses that cause hepatitis B, hemophilia A, bleeding disorders, immunodeficiency, hepatitis C, hypogammaglobulinemia, hemophilia B and human immunodeficiency virus (HIV). Apart from this, blood plasma derivatives assist in enhancing nutrition, controlling body temperature and coagulation of blood, maintaining osmotic pressure, enhancing respiration and excretion, and regulating acid-base balance. Blood plasma derivatives are commonly stored at hospitals, clinics, diagnostic centers and blood transfusion centers.

Blood Plasma Derivatives Market Trends:
The increasing geriatric population that are more susceptible to developing infectious diseases are creating a positive outlook for the market. Blood plasma contains immunoglobulins that play an important role in the development of immunity and maintain the osmotic pressure in blood vessels, which further prevents the onset immunodeficiency disorders and hemophilia. Moreover, the widespread product adoption to treat coronavirus disease (COVID-19) patients by convalescent plasma treatment is favoring the market growth. Additionally, various technological innovations in the fractionation process that aids in separating protein concentrates and various components of blood plasma for clinical purposes are providing a considerable boost to the market growth. In line with this, the development of advanced preservation methods, along with the significant improvements in encased procedures for developing targeted therapeutic products are further augmenting the market growth. Other factors, including significant growth in the healthcare industry, increasing awareness regarding blood and plasma donation and the implementation of various government initiatives to promote blood donation camps, are anticipated to drive the market further toward growth.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global blood plasma derivatives market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, application and end user.

Breakup by Type:

Albumin
Factor VIII
Factor IX
Immunoglobulin
Hyperimmune Globulin
Others

Breakup by Application:

Hemophilia
Hypogammaglobulinemia
Immunodeficiency Diseases
Von Willebrand’s Disease
Others

Breakup by End User:

Hospitals
Clinics
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Bayer AG, CSL Limited, Fusion Health Care Pvt. Ltd., Grifols S.A., Kedrion S.p.A., LFB S.A., Octapharma AG, Sanofi S.A. and Takeda Pharmaceutical Company Limited. Key Questions Answered in This Report:
How has the global blood plasma derivatives market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global blood plasma derivatives market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global blood plasma derivatives market and who are the key players?
What is the degree of competition in the industry?